Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS. Garralda E, et al. Among authors: abraham ak. ESMO Open. 2022 Dec;7(6):100639. doi: 10.1016/j.esmoop.2022.100639. Epub 2022 Dec 6. ESMO Open. 2022. PMID: 36493599 Free PMC article.
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. Siu LL, et al. Among authors: abraham ak. Clin Cancer Res. 2022 Jan 1;28(1):57-70. doi: 10.1158/1078-0432.CCR-21-2160. Epub 2021 Oct 1. Clin Cancer Res. 2022. PMID: 34598945 Free PMC article.
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. Siu LL, et al. Among authors: abraham ak. Clin Cancer Res. 2022 Apr 14;28(8):1734. doi: 10.1158/1078-0432.CCR-22-0564. Clin Cancer Res. 2022. PMID: 35419588 No abstract available.
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. Siu LL, et al. Among authors: abraham ak. Clin Cancer Res. 2022 Sep 15;28(18):4158. doi: 10.1158/1078-0432.CCR-22-2320. Clin Cancer Res. 2022. PMID: 36106403 Free PMC article. No abstract available.
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD, Jauslin PM, Kleijn HJ, de Miranda Silva C, Chain A, Bateman T, Shaw PM, Abraham AK, Kauh EA, Liu Y, Perini RF, de Alwis DP, Jain L. Marathe DD, et al. Among authors: abraham ak. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1499-1510. doi: 10.1002/psp4.13028. Epub 2023 Aug 28. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37596839 Free PMC article.
Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, Sinha V, de Alwis DP, Mayawala K. Li TR, et al. Among authors: abraham ak. Clin Pharmacol Ther. 2021 Jul;110(1):200-209. doi: 10.1002/cpt.2170. Epub 2021 Mar 8. Clin Pharmacol Ther. 2021. PMID: 33462831
53 results